BluntForceOptions

BluntForceOptions

Nebius (NBIS) has made a strong run but is now failing to break through the 200 SMA, a key resistance level that continues to hold. Without a decisive move higher, the stock looks vulnerable to a pullback toward support. I’m watching S-1 at $38.87 as the first key level. If it breaks, I expect further downside toward S-2 at $34.01. Given the recent price action,...

BluntForceOptions

Most are already familiar with the recent Nvidia (NVDA)-SoundHound (SOUN) news—the stock fell 28.1% on Feb 14 after Nvidia disclosed it had sold the remainder of its holdings in the AI voice company. Rather than rehashing the headlines, let’s focus on where things stand now. Since the sell-off, SOUN has been tracking the SMA 100 without a decisive breakout to the...

BluntForceOptions

Viking Therapeutics has been in a downtrend since late 2024, with price consistently making lower lows. However, since mid January, 2025, both the Relative Strength Index (RSI) and Stochastic Momentum Index (SMI) have been sloping upward, diverging from the price action, which continued to trend lower. IMO, this bullish divergence signals that selling momentum...

BluntForceOptions

Today's positive trial data pushed Solid Bioscience's stock above $7 before the offering news weighed on upside momentum. Despite this, I have my eye on a key multi-month trendline that suggests potential support around $4.48, which remains 11.17% above the offering price of $4.03. This level aligns with prior trendline resistance on the downtrend, now...